Total Payments
$143,604
2024 Payments
$1,500
Companies
8
Transactions
138
Payment Breakdown by Category
Consulting$75,304 (52.4%)
Other$51,390 (35.8%)
Travel$10,727 (7.5%)
Food & Beverage$4,524 (3.2%)
Research$1,659 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $75,304 | 20 | 52.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $43,390 | 15 | 30.2% |
| Travel and Lodging | $10,727 | 35 | 7.5% |
| Honoraria | $8,000 | 5 | 5.6% |
| Food and Beverage | $4,524 | 59 | 3.2% |
| Unspecified | $1,659 | 4 | 1.2% |
Payments by Type
General
$141,945
134 transactions
Research
$1,659
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alkermes, Inc. | $69,401 | 61 | $0 (2019) |
| Braeburn Pharmaceuticals, Inc. | $43,244 | 30 | $0 (2017) |
| Braeburn Inc. | $11,306 | 14 | $0 (2024) |
| Indivior Inc. | $5,945 | 13 | $0 (2023) |
| Titan Pharmaceuticals, Inc. | $5,625 | 2 | $0 (2021) |
| US WorldMeds, LLC | $4,947 | 13 | $0 (2017) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $3,115 | 4 | $0 (2021) |
| Orexo US, Inc. | $19.99 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,500 | 1 | Braeburn Inc. ($1,500) |
| 2023 | $6,553 | 8 | Braeburn Inc. ($6,517) |
| 2021 | $6,840 | 3 | Titan Pharmaceuticals, Inc. ($5,625) |
| 2020 | $39.80 | 2 | Orexo US, Inc. ($19.99) |
| 2019 | $21,703 | 24 | Alkermes, Inc. ($19,803) |
| 2018 | $39,073 | 40 | Alkermes, Inc. ($34,652) |
| 2017 | $67,894 | 60 | Braeburn Pharmaceuticals, Inc. ($43,244) |
All Payment Transactions
138 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/19/2024 | Braeburn Inc. | BRIXADI (Drug) | Honoraria | Cash or cash equivalent | $1,500.00 | General |
| Category: Opioid Use Disorder | ||||||
| 12/20/2023 | Braeburn Inc. | BRIXADI (Drug) | Honoraria | Cash or cash equivalent | $2,000.00 | General |
| Category: Opioid Use Disorder | ||||||
| 12/20/2023 | Braeburn Inc. | BRIXADI (Drug) | Honoraria | Cash or cash equivalent | $1,500.00 | General |
| Category: Opioid Use Disorder | ||||||
| 11/07/2023 | Braeburn Inc. | BRIXADI (Drug) | Honoraria | Cash or cash equivalent | $1,500.00 | General |
| Category: Opioid Use Disorder | ||||||
| 11/06/2023 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: OUD | ||||||
| 10/02/2023 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $0.17 | General |
| Category: Opioid Use Disorder | ||||||
| 10/01/2023 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: Opioid Use Disorder | ||||||
| 09/26/2023 | Braeburn Inc. | BRIXADI (Drug) | Honoraria | Cash or cash equivalent | $1,500.00 | General |
| Category: Opioid Use Disorder | ||||||
| 01/16/2023 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $21.93 | General |
| Category: OUD | ||||||
| 10/20/2021 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $1,215.00 | General |
| Category: PSYCHIATRY | ||||||
| 08/26/2021 | Titan Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 07/01/2021 | Titan Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,925.00 | General |
| 11/24/2020 | Orexo US, Inc. | Zubsolv (Drug) | Food and Beverage | Cash or cash equivalent | $19.99 | General |
| Category: Addiction Medicine | ||||||
| 01/16/2020 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $19.81 | General |
| Category: OUD | ||||||
| 12/19/2019 | Alkermes, Inc. | VIVITROL (Drug) | Food and Beverage | In-kind items and services | $10.99 | General |
| Category: CNS | ||||||
| 11/17/2019 | Alkermes, Inc. | — | Consulting Fee | Cash or cash equivalent | $8,000.00 | General |
| 07/12/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: PSYCHIATRY | ||||||
| 06/07/2019 | Alkermes, Inc. | VIVITROL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,600.00 | General |
| Category: CNS | ||||||
| 06/04/2019 | Alkermes, Inc. | VIVITROL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: CNS | ||||||
| 05/20/2019 | Alkermes, Inc. | VIVITROL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: CNS | ||||||
| 05/04/2019 | Alkermes, Inc. | VIVITROL (Drug) | Travel and Lodging | In-kind items and services | $573.10 | General |
| Category: CNS | ||||||
| 05/04/2019 | Alkermes, Inc. | VIVITROL (Drug) | Travel and Lodging | In-kind items and services | $174.41 | General |
| Category: CNS | ||||||
| 05/04/2019 | Alkermes, Inc. | VIVITROL (Drug) | Travel and Lodging | In-kind items and services | $87.75 | General |
| Category: CNS | ||||||
| 05/04/2019 | Alkermes, Inc. | VIVITROL (Drug) | Food and Beverage | In-kind items and services | $71.50 | General |
| Category: CNS | ||||||
| 05/04/2019 | Alkermes, Inc. | VIVITROL (Drug) | Food and Beverage | In-kind items and services | $48.60 | General |
| Category: CNS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Open-Label, Depot Buprenorphine RBP-6000 Treatment Extension Study in Subjects With Opioid Use Disorder | Indivior Inc. | $1,101 | 3 |
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess the Efficacy, Safety, and Tolerability of Multiple Subcutaneous Injections of Depot Buprenorphine RBP-6000 100 mg and 300 mg Over 24 Weeks in Treatment-Seeking Subjects With Opioid Use Disorder | Indivior Inc. | $558.29 | 1 |
About Dr. Genie Bailey, MD
Dr. Genie Bailey, MD is a Addiction Medicine healthcare provider based in Fall River, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1598852576.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Genie Bailey, MD has received a total of $143,604 in payments from pharmaceutical and medical device companies, with $1,500 received in 2024. These payments were reported across 138 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($75,304).
Ad
Practice Information
- Specialty Addiction Medicine
- Other Specialties Psychiatry
- Location Fall River, MA
- Active Since 10/09/2006
- Last Updated 03/18/2021
- Taxonomy Code 2084A0401X
- Entity Type Individual
- NPI Number 1598852576
Products in Payments
- Vivitrol 380 mg (Drug) $49,598
- Probuphine (Drug) $23,276
- CAM2038 $14,004
- VIVITROL (Drug) $11,803
- BRIXADI (Drug) $8,017
- SUBOXONE SUBLINGUAL FILM (Drug) $4,212
- REXULTI (Drug) $3,115
- SUBLOCADE (Drug) $1,733
- CAM2038q1w $266.86
- Zubsolv (Drug) $19.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.